VANCOUVER GENERAL HOSPITAL
CSU PHARMACEUTICAL SCIENCES
NON-FORMULARY DRUG DATA SHEET

DRUG NAME
ceftolozane-tazobactam

ALTERNATE NAME
ZERBAXA™

MANUFACTURER
Merck Canada

STRENGTH
1500 mg (ceftolozane 1000 mg and tazobactam 500 mg)

DOSAGE FORM
Injection

INDICATIONS
For treatment of infections caused by microorganisms susceptible to ceftolozane-tazobactam

DOSAGE

Creatinine clearance	Dosage
greater than 50 mL/minute	1500 mg IV Q8H
30 to 50 mL/minute	750 mg IV Q8H
15 to 29 mL/minute	375 mg IV Q8H
End-stage renal disease on hemodialysis	750 mg load, then 150 mg IV every 8 hours (dosed after dialysis on dialysis days)

Preparation instructions for Pharmacy:
Reconstitute with 10 mL of sterile water for injection and swirl to dissolve. (Concentration ~ 132 mg/mL)
Reconstituted vials are stable for 1 hour
Dilute in 100 mL sodium chloride 0.9% or dextrose 5% solution
Diluted solutions are stable for 24 hours at room temperature and 7 days in the fridge

Dose	Approximate volume of reconstituted solution
1500 mg	11.4 mL
750 mg	5.7 mL
375 mg	2.9 mL
150 mg	1.2 mL

ADMINISTRATION
- Infuse over 60 minutes
- Do not give IV direct
- Do not administer with any other drug in the same IV line

KNOWN SIDE EFFECTS*
- Serious and occasionally fatal hypersensitivity (anaphylactic) reactions in patients with previous severe hypersensitivities to beta-lactams
- Nausea, diarrhea, headache and pyrexia

SPECIAL PRECAUTIONS
- Contraindicated in patients with known serious hypersensitivities (anaphylaxis) to this drug or to penicillins, cephalosporins, or other beta-lactams
- Monitor renal function and adjust dose accordingly
- Store vials in the refrigerator and protect from light
- Please refer to the ZERBAXA™ product monograph for more detailed information
  http://www.merck.ca/assets/en/pdf/products/ZERBAXA-PM_E.pdf

***REPORT ANY ADVERSE DRUG REACTIONS TO CSU PHARMACEUTICAL SCIENCES**